AbbVie (ABBV) Competitors

$163.81
+3.00 (+1.87%)
(As of 05/3/2024 ET)

ABBV vs. MRK, JNJ, PFE, BMY, ZTS, MRNA, IQV, IDXX, BNTX, and ILMN

Should you be buying AbbVie stock or one of its competitors? The main competitors of AbbVie include Merck & Co., Inc. (MRK), Johnson & Johnson (JNJ), Pfizer (PFE), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Moderna (MRNA), IQVIA (IQV), IDEXX Laboratories (IDXX), BioNTech (BNTX), and Illumina (ILMN). These companies are all part of the "medical" sector.

AbbVie vs.

AbbVie (NYSE:ABBV) and Merck & Co., Inc. (NYSE:MRK) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, community ranking, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

In the previous week, AbbVie had 36 more articles in the media than Merck & Co., Inc.. MarketBeat recorded 61 mentions for AbbVie and 25 mentions for Merck & Co., Inc.. Merck & Co., Inc.'s average media sentiment score of 0.70 beat AbbVie's score of 0.54 indicating that Merck & Co., Inc. is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AbbVie
22 Very Positive mention(s)
6 Positive mention(s)
15 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Positive
Merck & Co., Inc.
12 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive

AbbVie received 334 more outperform votes than Merck & Co., Inc. when rated by MarketBeat users. Likewise, 73.09% of users gave AbbVie an outperform vote while only 66.97% of users gave Merck & Co., Inc. an outperform vote.

CompanyUnderperformOutperform
AbbVieOutperform Votes
1301
73.09%
Underperform Votes
479
26.91%
Merck & Co., Inc.Outperform Votes
967
66.97%
Underperform Votes
477
33.03%

AbbVie has higher earnings, but lower revenue than Merck & Co., Inc.. AbbVie is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbbVie$54.40B5.33$4.86B$3.3748.61
Merck & Co., Inc.$60.12B5.37$365M$0.90141.68

AbbVie has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500.

AbbVie pays an annual dividend of $6.20 per share and has a dividend yield of 3.8%. Merck & Co., Inc. pays an annual dividend of $3.08 per share and has a dividend yield of 2.4%. AbbVie pays out 184.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Merck & Co., Inc. pays out 342.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AbbVie is clearly the better dividend stock, given its higher yield and lower payout ratio.

AbbVie has a net margin of 11.02% compared to Merck & Co., Inc.'s net margin of 3.76%. AbbVie's return on equity of 165.18% beat Merck & Co., Inc.'s return on equity.

Company Net Margins Return on Equity Return on Assets
AbbVie11.02% 165.18% 14.40%
Merck & Co., Inc. 3.76%14.15%5.24%

AbbVie currently has a consensus price target of $174.31, indicating a potential upside of 6.41%. Merck & Co., Inc. has a consensus price target of $131.33, indicating a potential upside of 3.00%. Given AbbVie's stronger consensus rating and higher probable upside, research analysts clearly believe AbbVie is more favorable than Merck & Co., Inc..

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AbbVie
0 Sell rating(s)
3 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.77
Merck & Co., Inc.
1 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.58

70.2% of AbbVie shares are held by institutional investors. Comparatively, 76.1% of Merck & Co., Inc. shares are held by institutional investors. 0.3% of AbbVie shares are held by insiders. Comparatively, 0.1% of Merck & Co., Inc. shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

AbbVie beats Merck & Co., Inc. on 15 of the 20 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABBV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ABBV vs. The Competition

MetricAbbViePharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$290.05B$6.60B$4.94B$17.42B
Dividend Yield3.81%2.79%2.86%3.58%
P/E Ratio48.6119.31263.6925.52
Price / Sales5.33329.472,352.8612.11
Price / Cash10.2332.2848.1117.50
Price / Book28.346.104.854.92
Net Income$4.86B$140.85M$103.62M$964.63M
7 Day Performance2.62%5.25%3.79%1.76%
1 Month Performance-7.63%-5.35%-3.29%-1.96%
1 Year Performance9.76%2.07%6.11%100.34%

AbbVie Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MRK
Merck & Co., Inc.
4.7683 of 5 stars
$129.19
-0.7%
$131.33
+1.7%
+7.9%$327.24B$60.12B143.5472,000
JNJ
Johnson & Johnson
4.9041 of 5 stars
$144.61
-1.5%
$175.86
+21.6%
-8.4%$348.48B$85.16B9.02131,900
PFE
Pfizer
4.9789 of 5 stars
$25.61
-0.1%
$36.33
+41.9%
-27.7%$145.02B$58.50B71.1488,000Earnings Report
Analyst Report
Analyst Revision
BMY
Bristol-Myers Squibb
4.9431 of 5 stars
$43.96
-1.5%
$60.00
+36.5%
-34.0%$89.11B$45.01B-14.1834,100Options Volume
ZTS
Zoetis
4.9049 of 5 stars
$159.17
-0.3%
$218.00
+37.0%
-6.0%$72.80B$8.54B31.3914,100Earnings Report
Analyst Report
Analyst Revision
News Coverage
MRNA
Moderna
3.4358 of 5 stars
$110.31
-1.2%
$126.49
+14.7%
-3.9%$42.24B$6.85B-8.895,600Earnings Report
Analyst Report
Insider Selling
Analyst Revision
News Coverage
Gap Up
IQV
IQVIA
4.7919 of 5 stars
$231.80
-1.6%
$256.80
+10.8%
+19.4%$42.07B$14.98B31.8087,000Analyst Report
News Coverage
IDXX
IDEXX Laboratories
4.1236 of 5 stars
$492.76
-2.5%
$591.50
+20.0%
+0.4%$40.92B$3.66B48.9311,000Analyst Downgrade
Analyst Revision
News Coverage
Gap Up
BNTX
BioNTech
2.8953 of 5 stars
$88.82
+1.0%
$120.40
+35.6%
-15.8%$21.12B$4.13B21.566,133Upcoming Earnings
News Coverage
ILMN
Illumina
4.9399 of 5 stars
$123.05
-1.3%
$167.70
+36.3%
-40.0%$19.60B$4.50B-16.769,300Earnings Report
Analyst Downgrade
News Coverage
Gap Up

Related Companies and Tools

This page (NYSE:ABBV) was last updated on 5/4/2024 by MarketBeat.com Staff

From Our Partners